Format
Sort by
Items per page

Send to

Choose Destination

Best matches for ULIPRISTAL/TU:

Endometrial changes during ulipristal acetate use: A systematic review. De Milliano I et al. Eur J Obstet Gynecol Reprod Biol. (2017)

Ulipristal acetate versus leuprolide acetate for uterine fibroids. Donnez J et al. N Engl J Med. (2012)

Long-term medical management of uterine fibroids with ulipristal acetate. Donnez J et al. Fertil Steril. (2016)

Search results

Items: 1 to 20 of 297

1.

Ulipristal Acetate for Disseminated Peritoneal Leiomyomatosis.

Benlolo S, Papillon-Smith J, Murji A.

Obstet Gynecol. 2019 Mar;133(3):434-436. doi: 10.1097/AOG.0000000000003112.

PMID:
30741799
2.

Adverse symptoms during short-term use of ulipristal acetate in women with uterine myomas and/or adenomyosis.

Hong YH, Han SJ, Lee D, Kim SK, Jee BC.

J Obstet Gynaecol Res. 2019 Apr;45(4):865-870. doi: 10.1111/jog.13917. Epub 2019 Jan 24.

PMID:
30675965
3.

Birth Control Pills and Thrombotic Risks: Differences of Contraception Methods with and without Estrogen.

Rott H.

Hamostaseologie. 2019 Feb;39(1):42-48. doi: 10.1055/s-0039-1677806. Epub 2019 Jan 22. Review.

PMID:
30669160
4.

Interventions for emergency contraception.

Shen J, Che Y, Showell E, Chen K, Cheng L.

Cochrane Database Syst Rev. 2019 Jan 20;1:CD001324. doi: 10.1002/14651858.CD001324.pub6.

PMID:
30661244
5.

Fibroid management in premenopausal women.

Donnez J, Courtoy GE, Dolmans MM.

Climacteric. 2019 Feb;22(1):27-33. doi: 10.1080/13697137.2018.1549216. Epub 2019 Jan 2.

PMID:
30601065
6.

Ulipristal Acetate Mediates Decreased Proteoglycan Expression Through Regulation of Nuclear Factor of Activated T-Cells (NFAT5).

Britten JL, Malik M, Lewis TD, Catherino WH.

Reprod Sci. 2019 Feb;26(2):184-197. doi: 10.1177/1933719118816836. Epub 2018 Dec 19.

PMID:
30567472
7.

Selective Progesterone Receptor Modulators for the Medical Treatment of Uterine Fibroids with a Focus on Ulipristal Acetate.

Rabe T, Saenger N, Ebert AD, Roemer T, Tinneberg HR, De Wilde RL, Wallwiener M.

Biomed Res Int. 2018 Jun 24;2018:1374821. doi: 10.1155/2018/1374821. eCollection 2018. Review. Erratum in: Biomed Res Int. 2018 Nov 28;2018:6124628.

8.

Sonographic and hysteroscopic endometrial examination in women treated with ulipristal acetate: Exploratory findings at a tertiary referral center.

Gracia M, Nonell R, Ros C, Rius M, Quintas L, Martínez-Zamora MÁ, Carmona F.

Eur J Obstet Gynecol Reprod Biol. 2019 Jan;232:40-45. doi: 10.1016/j.ejogrb.2018.11.009. Epub 2018 Nov 6.

PMID:
30468982
9.

Liver safety parameters of ulipristal acetate for the treatment of uterine fibroids: a comprehensive review of the clinical development program.

Donnez J, Arriagada P, Marciniak M, Larrey D.

Expert Opin Drug Saf. 2018 Dec;17(12):1225-1232. doi: 10.1080/14740338.2018.1550070. Epub 2018 Nov 29. Review.

PMID:
30460871
10.

Pericoital contraception.

Cahill EP, Blumenthal PD.

Curr Opin Obstet Gynecol. 2018 Dec;30(6):400-406. doi: 10.1097/GCO.0000000000000491. Review.

PMID:
30399016
11.

[Emergency contraception: CNGOF Contraception Guidelines].

Hamdaoui N, Cardinale C, Agostini A.

Gynecol Obstet Fertil Senol. 2018 Dec;46(12):799-805. doi: 10.1016/j.gofs.2018.10.006. Epub 2018 Oct 30. Review. French.

PMID:
30389544
12.

Ulipristal acetate therapy increases ultrasound features of adenomyosis: a good treatment given in an erroneous diagnosis of uterine fibroids.

Conway F, Morosetti G, Camilli S, Martire FG, Sorrenti G, Piccione E, Zupi E, Exacoustos C.

Gynecol Endocrinol. 2019 Mar;35(3):207-210. doi: 10.1080/09513590.2018.1505846. Epub 2018 Nov 1.

PMID:
30382803
13.

Resistance of primary breast cancer cells with enhanced pluripotency and stem cell activity to sex hormonal stimulation and suppression.

Nasr M, Farghaly M, Elsaba T, El-Mokhtar M, Radwan R, Elsabahy M, Abdelkareem A, Fakhry H, Mousa N.

Int J Biochem Cell Biol. 2018 Dec;105:84-93. doi: 10.1016/j.biocel.2018.10.005. Epub 2018 Oct 22.

PMID:
30359767
14.

Choice of contraceptives.

[No authors listed]

Med Lett Drugs Ther. 2018 Oct 8;60(1557):161-168. No abstract available.

PMID:
30335731
15.

Ulipristal acetate (Esmya): restrictions on use.

[No authors listed]

Drug Ther Bull. 2018 Nov;56(11):127. doi: 10.1136/dtb.2018.11.000033. Epub 2018 Oct 8.

PMID:
30297449
16.

[Ulipristal acetate and SPRM: A new entity for the therapeutic strategy for symptomatic myomas].

Fernandez H.

Gynecol Obstet Fertil Senol. 2018 Nov;46(10-11):671-672. doi: 10.1016/j.gofs.2018.09.003. Epub 2018 Oct 4. French. No abstract available. Erratum in: Gynecol Obstet Fertil Senol. 2019 Jan;47(1):90.

PMID:
30293948
17.

A-Kinase Anchoring Protein 13 (AKAP13) Augments Progesterone Signaling in Uterine Fibroid Cells.

Ng SSM, Jorge S, Malik M, Britten J, Su SC, Armstrong CR, Brennan JT, Chang S, Baig KM, Driggers PH, Segars JH.

J Clin Endocrinol Metab. 2019 Mar 1;104(3):970-980. doi: 10.1210/jc.2018-01216.

PMID:
30239831
18.

Liver injury and ulipristal acetate: an overstated tragedy?

Donnez J.

Fertil Steril. 2018 Sep;110(4):593-595. doi: 10.1016/j.fertnstert.2018.06.044. No abstract available.

PMID:
30196943
19.

Failure of ulipristal acetate treatment as an indication for uterine malignancy: Two case reports.

Santoro A, Angelico G, Arciuolo D, Inzani F, Fanfani F, Romualdi D, Scambia G, Zannoni GF.

Medicine (Baltimore). 2018 Aug;97(31):e11532. doi: 10.1097/MD.0000000000011532.

20.

Alternatives to excisional therapy: a clinical review of our current options to conservatively manage symptomatic leiomyomas.

Ito T, Mattingly PJ, Jan AG, Biscette SM, Kim JHJ.

Curr Opin Obstet Gynecol. 2018 Aug;30(4):279-286. doi: 10.1097/GCO.0000000000000470. Review.

PMID:
29975307

Supplemental Content

Loading ...
Support Center